Eris acquires Indian branded generics business of Bangalore based Strides
November 2017: Eris Lifesciences Ltd (Eris) acquired the Indian branded generics business of Strides Shasun Ltd (Strides) for an aggregate cash consideration of INR 500 crores. With this acquisition, Eris acquired the marketing and distribution rights for India for 130+ brands in the Neurology, Psychiatry, Nutraceuticals and Women Healthcare therapy areas. The Indian branded generics business being divested by Strides had sales of INR 181 crores for FY 2017.
Eris acquires Pune based UTH Healthcare
October 2017: Eris Lifesciences Ltd (Eris) has acquired the entire shareholding of UTH Healthcare Ltd (UTH) for an all-cash consideration on INR 12.85 crores.
UTH is largely engaged in the segments of Obesity, Diabetes, Gestational diabetes mellitus, Maternal nutrition, and Cardio-vascular diseases. The acquisition provides Eris with a portfolio of products that complement its other offerings.
Eris Lifesciences receives ‘The Best Asian Healthcare Brand Award 2017’
The second edition of The Economic Times Best Asian Healthcare Brands 2017 awards were announced in Dubai in September 2017
48 companies received awards amongst 250 shortlisted nominees which were selected on basis of key attributes like innovation, brand value, brand recall, consumer satisfaction, customer service and quality associated with the Brand.
Eris Lifesciences was awarded Asian Healthcare Brand Award for 2017
April 2013 Frost & Sullivan presented the 2013 Competitive Strategy Leadership Award to Eris in the pharmaceutical industry. Eris was awarded for its unprecedented growth in the IPM for their innovation in the healthcare sector.
ChrysCapital has acquired a stake in Eris Lifesciences Ltd
September 2011 ChrysCapital has acquired a stake in Eris Lifesciences Ltd, a branded formulations company based out of Ahmedabad. Founded in 2007, the company operates with a focus on cardiovascular, diabetes, gastro and ortho segments.